Search Results

Treos Bio Limited announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 American Society of Clinical Oncology Annual Meeting.

Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Azitra, Inc. today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.

EditCo Bio, Inc., a leader in genome engineering innovation, announced the expansion of its T-cell editing portfolio with the launch of Knockout CD8+ T-cell Pools.